Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the allowance of a new patent in Japan, the fourth to be granted in that country and the 26th worldwide. “Entitled Lipophilic Active Agent Infused Compositions with Reduced Food Effect, this is the first patent issued from Lexaria’s seventh patent family and refers to tetrahydrocannabinol (‘THC’). The new patent acknowledges DehydraTECH(TM)’s ability to deliver active pharmaceutical ingredients (‘APIs’) more efficiently, in a process known as absorption, regardless of the presence of food in the gastrointestinal system. Ordinarily, food impacts drug absorption by physically interacting with drugs, altering the pH, stimulating bile flow, slowing gastric emptying time, or increasing splanchnic blood flow. But DehydraTECH, Lexaria’s patented drug delivery technology, delivers drugs more consistently into the bloodstream regardless of this food effect. The drug delivery technology achieves this through its use of fatty acid oil,” a recent article reads. “Lexaria’s technology joins the API’s molecules in what is believed to be a ‘barbell-shaped’ structure that allows the body to detect both molecules while enhancing taste and absorption. The body’s detection and natural processing of the long chain fatty acid is part of Lexaria’s clever patented process that also enhances API absorption.”
To view the full article, visit https://cnw.fm/BapRq
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.